Inhibition of prostate cancer growth by estramustine and colchicine

Marwan Fakih, Tracy Replogle, Jeff E. Lehr, Kenneth J. Pienta, Alan Yagoda

Research output: Contribution to journalArticlepeer-review


Hormone‐refractory prostate cancer continues to be associated with a very poor prognosis. Agents that inhibit microtubule function have been found to be cytotoxic to prostate cancer cells in preclinical and clinical settings. It was the aim of this study to assess the activity of estramustine and colchicine, two microtubule inhibitors, in hormone‐refractory prostate cancer. In clinically achievable concentrations, the combination of estramustine and colchicine was cytotoxic to both the Dunning rat prostate adenocarcinoma cell line MAT‐LyLu (MLL) and human prostate cancer cells (PC‐3). Microtubule function was assessed in vitro to evaluate possible mechanisms of action. In motility and cell cycle analysis assays, estramustine and colchicine inhibited cellular motility but not cell cycle transit. In vivo, these two agents both inhibited the growth of implanted Dunning rat prostate adenocarcinoma MLL cells but did not appear to have additive effects. The use of oral colchicine in the treatment of hormone‐refractory prostate cancer requires further investigation.

Original languageEnglish (US)
Pages (from-to)310-315
Number of pages6
JournalThe Prostate
Issue number6
StatePublished - Jun 1995
Externally publishedYes


  • Dunning Mat‐LyLu
  • PC‐3
  • colchicine
  • estramustine
  • prostate cancer

ASJC Scopus subject areas

  • Oncology
  • Urology


Dive into the research topics of 'Inhibition of prostate cancer growth by estramustine and colchicine'. Together they form a unique fingerprint.

Cite this